PSMD3

PSMD3 is a non-ATPase subunit of the 19S regulatory particle lid subcomplex of the 26S proteasome, essential for proteasome assembly, substrate-selective ubiquitin-dependent proteolysis, and stabilization of the proteasome-associated deubiquitinase RPN11/PSMD14. Conditional inactivation of its yeast orthologue Rpn3 impairs degradation of specific cell-cycle regulators (cyclins Cln2, Clb5, Clb2 and the anaphase inhibitor Pds1) while sparing others such as Sic1, demonstrating that individual lid subunits confer substrate selectivity to the proteasome (PMID:10490625). PSMD3 physically interacts with and is required for the stability and proteasomal incorporation of the deubiquitinase Rpn11; loss of Rpn3 causes accumulation of polyubiquitinated proteins and defective 20S–19S particle association (PMID:21619884). In human cancer cells, PSMD3 stabilizes HER2 by shielding it from ubiquitin-mediated lysosomal degradation and promotes NF-κB activity, linking proteasome subunit function to oncogenic signaling (PMID:31013812, PMID:33712704).

1. 1996 High

   Biochemical reconstitution and fractionation studies established the subunit composition of the 26S proteasome 19S regulatory particle, placing p58/PSMD3 among the non-ATPase subunits that constitute the lid and base subcomplexes required for ubiquitinated substrate recognition and gating of the 20S core.

   Evidence Biochemical fractionation, reconstitution of 26S from 20S and 19S particles, cross-linking, and subunit purification (review of primary data)

   PMID:8811196

   Open questions at the time

   • Specific functional contribution of p58/PSMD3 versus other non-ATPase subunits was not resolved
   • No substrate-level analysis of p58 requirement
2. 1997 High

   Identification of the yeast orthologue Sun2p/Rpn3 and its biochemical co-sedimentation with proteasome components confirmed PSMD3 as a bona fide 26S proteasome subunit and showed that the N-terminal 150 amino acids are dispensable for core proteasome function.

   Evidence Glycerol density gradient centrifugation, multicopy suppressor screen, complementation with truncation mutants in yeast

   PMID:9017604

   Open questions at the time

   • Role of the dispensable N-terminal domain remained undefined
   • Whether Rpn3 contributes to proteolysis of specific substrates was untested
3. 1999 High

   Conditional inactivation of Rpn3 revealed that this lid subunit is selectively required for ubiquitin-dependent degradation of specific cell-cycle substrates (Cln2, Clb5, Clb2, Pds1) but not Sic1, establishing that individual 19S non-ATPase subunits confer substrate selectivity to the proteasome.

   Evidence Temperature-sensitive rpn3 alleles, pulse-chase and cycloheximide-chase proteolysis assays, flow cytometry for cell-cycle arrest, comparison with rpn12 mutants in yeast

   PMID:10490625

   Open questions at the time

   • Molecular basis of substrate selectivity — whether Rpn3 contacts substrates directly or acts indirectly — was not determined
   • Generalizability to mammalian proteasomes was not tested
4. 2009 Medium

   Proteomic mapping of the human deubiquitinase interaction network confirmed PSMD3 as a stable lid subunit of the human 19S regulatory particle and revealed its physical association with proteasome-associated deubiquitinases including USP14.

   Evidence Tandem affinity purification mass spectrometry (TAP-MS) with CompPASS confidence scoring in human cells

   PMID:19615732

   Open questions at the time

   • Direct versus indirect nature of the PSMD3–USP14 association was not resolved
   • Functional consequence of this interaction was not tested
5. 2011 High

   Rpn3 was shown to physically interact with the deubiquitinase Rpn11 and to be required for Rpn11 stability and incorporation into mature 26S proteasomes, explaining how Rpn3 loss leads to defective 20S–19S association and polyubiquitin accumulation.

   Evidence Co-immunoprecipitation, glycerol gradient fractionation, pulse-chase Rpn11 stability assays, rpn3 × rpn11 synthetic epistasis in yeast

   PMID:21619884

   Open questions at the time

   • Structural basis of the Rpn3–Rpn11 interface was not resolved
   • Whether this mechanism is conserved in the human PSMD3–PSMD14 pair was not directly demonstrated
6. 2019 Medium

   A non-canonical, proteasome-external role for human PSMD3 was proposed: PSMD3 physically interacts with HER2 and shields it from ubiquitin-mediated lysosomal degradation in breast cancer cells, with knockdown reducing HER2 levels and impairing cancer cell viability.

   Evidence Co-immunoprecipitation, siRNA knockdown, ubiquitination assay, LAMP-1 localization by immunostaining, colony formation and apoptosis assays in breast cancer cell lines

   PMID:31013812

   Open questions at the time

   • Whether PSMD3 acts on HER2 as part of the intact 26S proteasome or independently was not distinguished
   • Single-lab observation without independent replication
   • Direct binding domain on PSMD3 or HER2 was not mapped
7. 2021 Medium

   PSMD3 was linked to NF-κB activation in CML cells, with knockdown reducing NF-κB protein levels, nuclear activity, and leukemic cell survival while sparing normal progenitors, suggesting a disease-relevant signaling role for this proteasome subunit.

   Evidence siRNA knockdown, NF-κB luciferase reporter, nucleocytoplasmic fractionation, immunoblot, cell viability and apoptosis assays in CML cell lines and patient samples

   PMID:33712704

   Open questions at the time

   • Whether PSMD3 promotes NF-κB via proteasomal IκB degradation or a distinct mechanism was not resolved
   • Single-lab study; independent validation needed
   • Relationship between the HER2-stabilizing and NF-κB-activating roles is unknown

• The structural basis of PSMD3's substrate-selective contribution to proteasomal degradation, the mechanism by which it stabilizes RPN11/PSMD14 during lid assembly, and whether its reported non-canonical roles in HER2 stabilization and NF-κB activation reflect proteasome-dependent or independent functions remain unresolved.
• No high-resolution structure of PSMD3 in context of the human 19S lid with bound substrate
• Proteasome-dependent versus proteasome-independent mechanisms for HER2 and NF-κB effects not distinguished
• In vivo relevance of PSMD3 substrate selectivity in mammalian systems not tested